Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Galmed Pharmaceuticals Ltd. (GLMD)
Ramat Gan, IL
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.23% | +30.49% | +32.21% | +23.24% | -19.82% | +0.41% | -47.30% | -98.54% | -99.84% | -99.90% | -99.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+70.4% ★ Q1'26: +53.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +544.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+363.2% Q1'26: +270.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
467.0K
est: 766.6K (-39.1%)
|
1.09M
est: 1.03M (+5.8%)
|
2.04M
est: 2.17M (-5.9%)
|
—
|
—
est: 5.66M (-100.0%)
|
5.72M
5.72M – 5.72M
+1.0% YoY
|
5.80M
5.80M – 5.80M
+1.4% YoY
|
5.00M
5.00M – 5.00M
-13.8% YoY
|
17.45M
17.45M – 17.45M
+248.8% YoY
|
—
— – —
-100.0% YoY
|
| EBITDA |
-16.71M
|
-12.13M
|
-10.33M
|
-7.42M
|
-10.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-16.88M
|
-12.36M
|
-10.72M
|
-7.50M
|
-10.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-16.95M
est: -232.56M (+92.7%)
|
-12.30M
est: -158.50M (+92.2%)
|
-9.86M
est: -82.73M (+88.1%)
|
-7.52M
est: -14.41M (+47.8%)
|
-10.31M
est: -9.96M (-3.5%)
|
-6.73M
-6.73M – -6.73M
+32.5% YoY
|
-3.88M
-3.88M – -3.88M
+42.3% YoY
|
-3.28M
-3.28M – -3.28M
+15.6% YoY
|
-7.80M
-7.80M – -7.80M
-138.2% YoY
|
-7.59M
-7.59M – -7.59M
+2.8% YoY
|
| SGA |
3.08M
|
3.80M
|
4.44M
|
3.30M
|
3.64M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-22.36
est: -249.84 (+91.1%)
|
-14.77
est: -170.28 (+91.3%)
|
-8.15
est: -88.88 (+90.8%)
|
-8.08
est: -15.48 (+47.8%)
|
-2.39
est: -2.31 (-3.5%)
|
-1.56
-1.56 – -1.56
+32.5% YoY
|
-0.90
-0.90 – -0.90
+42.3% YoY
|
-0.76
-0.76 – -0.76
+15.6% YoY
|
-1.81
-1.81 – -1.81
-138.2% YoY
|
-1.76
-1.76 – -1.76
+2.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yarom Medical Research Ltd. | 3.42M | 16.00% | — | 3.42M | — | 3.42M | CO | Israel | 2021-02-12 | ↗ |
| 2 | BVF Inc. | 1.80M | 8.40% | — | — | — | 1.80M | CO | — | 2021-02-12 | ↗ |
| 3 | BVF Partners L.P. | 1.80M | 8.40% | — | — | — | 1.80M | IA, PN | — | 2021-02-12 | ↗ |
| 4 | Mark N. Lampert | 1.80M | 8.40% | — | — | — | 1.80M | IN | — | 2021-02-12 | ↗ |
| 5 | BVF GP HOLDINGS LLC | 1.63M | 7.70% | — | — | — | 1.63M | OO | — | 2021-02-12 | ↗ |
| 6 | BVF I GP LLC | 923.4K | 4.30% | — | — | — | 923.4K | OO | — | 2021-02-12 | ↗ |
| 7 | Biotechnology Value Fund, L.P. | 923.4K | 4.30% | — | — | — | 923.4K | PN | — | 2021-02-12 | ↗ |
| 8 | BVF II GP LLC | 710.9K | 3.30% | — | — | — | 710.9K | OO | — | 2021-02-12 | ↗ |
| 9 | Biotechnology Value Fund II, L.P. | 710.9K | 3.30% | — | — | — | 710.9K | PN | — | 2021-02-12 | ↗ |
| 10 | Ibex GP LLC | 355.6K | 1.40% | 355.6K | — | 355.6K | — | OO | Citizenship or Place of Organization | 2022-01-27 | ↗ |
| 11 | Ibex Investment Holdings II LLC | 355.6K | 1.40% | 355.6K | — | 355.6K | — | OO | Citizenship or Place of Organization | 2022-01-27 | ↗ |
| 12 | Ibex Investment Holdings LLC | 355.6K | 1.40% | 355.6K | — | 355.6K | — | OO | Citizenship or Place of Organization | 2022-01-27 | ↗ |
| 13 | Ibex Investors LLC | 355.6K | 1.40% | 355.6K | — | 355.6K | — | OO | USA | 2022-01-27 | ↗ |
| 14 | Ibex Israel Fund LLLP | 355.6K | 1.40% | 355.6K | — | 355.6K | — | PN | Citizenship or Place of Organization | 2022-01-27 | ↗ |
| 15 | Justin B. Borus | 355.6K | 1.40% | 355.6K | — | 355.6K | — | IN | Citizenship or Place of Organization | 2022-01-27 | ↗ |
| 16 | Daniel Mack | 297.9K | 1.20% | — | 297.9K | — | — | HC | USA | 2022-02-14 | ↗ |
| 17 | Nantahala Capital Management, LLC | 297.9K | 1.20% | — | 297.9K | — | — | IA | MA | 2022-02-14 | ↗ |
| 18 | Wilmot B. Harkey | 297.9K | 1.20% | — | 297.9K | — | — | HC | USA | 2022-02-14 | ↗ |
| 19 | CVI Investments, Inc. | 207.6K | 9.90% | — | 207.6K | — | 207.6K | CO | Cayman Islands | 2023-07-21 | ↗ |
| 20 | Heights Capital Management, Inc. | 207.6K | 9.90% | — | 207.6K | — | 207.6K | CO | Cayman Islands | 2023-07-21 | ↗ |
| 21 | BVF Partners OS Ltd. | 135.4K | 1.00% | — | — | — | 135.4K | CO | — | 2021-02-12 | ↗ |
| 22 | Biotechnology Value Trading Fund OS LP | 135.4K | 1.00% | — | — | — | 135.4K | PN | — | 2021-02-12 | ↗ |
| 23 | MASAYA OTSUKA | 63.8K | 9.90% | 63.8K | — | 63.8K | — | IN | JAPAN | 2024-09-20 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Allen Baharaff | Co-Founder, President, Chief Executive Officer & Chairman | 2M | male |
| Yohai Stenzler | Chief Accounting Officer | 341.3K | male |
| Guy Nehemya | Chief Operating Officer & Data Protection Officer | 333.7K | male |
| Doron Cohen | Chief Financial Officer | 286.6K | male |
| Tali Gorfine | Medical Consultant | 202.8K | — |
| Liat Hayardeny | Chief Scientific Officer | 47.9K | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GLMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
